ADRX.US ADARx Pharmaceuticals, Inc. Common Stock

Healthcare Biotechnology USA Stocks
15.02 USD
Close of Nov 13, 2026
12.50 23.21
Market cap
USD 1.66B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ADRX.US undervalued?

Graham number

The Graham number of ADARx Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ADARx Pharmaceuticals, Inc. Common Stock fundamental analysis

No fundamental analysis for ADARx Pharmaceuticals, Inc. Common Stock yet.

ADARx Pharmaceuticals, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ADARx Pharmaceuticals, Inc. Common Stock

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and…

Full company profile